stockrowPluri Inc.
PLUR Healthcare Biotechnology
Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025.
- Revenue
- −15.8%
- EPS
- +44.8%
- Free cash flow
- +25.0%
- Total debt
- +3.43%
Quarter to June 2026, against a year earlier
Follow PLUR
Alert me
Pluri Inc. (PLUR) EV/Sales
As of 6 November 2026, Pluri Inc. (PLUR) trades at a EV/Sales of 32.0×. Over the past ten years it has ranged from −39.4× (September 2022) to 3,287× (December 2020); the current reading is higher than 22% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 40.1× | (14.35%) |
| FY2025 | 46.8× | (37.97%) |
| FY2024 | 75.5× | 64.99% |
| FY2023 | 45.8× | 137.30% |
| FY2022 | 19.3× | (98.72%) |
| FY2020 | 1,508× | 224.23% |
| FY2019 | 465× | 1,223.95% |
| FY2018 | 35.1× | 41.41% |
| FY2016 | 24.8× | (92.41%) |
| FY2015 | 327× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 40.1× | (17.53%) |
| Mar 2026 | 48.6× | 51.24% |
| Dec 2025 | 32.2× | (44.84%) |
| Sep 2025 | 58.3× | 24.48% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VAXX Vaxxinity, Inc. compare | −94.2× |
| ABOS Acumen Pharmaceuticals, Inc. compare | −25.4× |
| ATYR aTyr Pharma, Inc. compare | −3.5× |
| NEUP Neuphoria Therapeutics Inc. compare | −0.4× |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| MRKR MARKER THERAPEUTICS, INC. compare | 1.9× |
| KYNB Kyntra Bio Inc compare | 15.5× |
| PLUR Pluri Inc. | 32.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)